| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Tetracaine HCl Basic Information:
Pharmaceutical Anesthetic Purity HCl Powder CAS 136-47-0 Tetracaine Lidocaine
Lidocaine hydrochloride undergoes rapid metabolism in the liver, with both metabolites and unchanged drug being excreted via the kidneys. The biotransformation process encompasses oxidative N-dealkylation, ring hydroxylation, amide linkage cleavage, and conjugation. Notably, N-dealkylation, the principal pathway, produces metabolites monoethylglycinexylidide and glycinexylidide, which exhibit pharmacological and toxicological actions similar to Lidocaine hydrochloride, though they are less potent. About 90% of administered Lidocaine hydrochloride is excreted as various metabolites, while less than 10% is excreted unchanged. The predominant urinary metabolite is a conjugate of 4-hydroxy-2,6-dimethylaniline.
Lidocaine HCl is a potent amide local anesthetic, renowned for its efficacy and reliability.
As the dosage increases, both the therapeutic effects and toxicity levels rise. At sub-toxic plasma concentrations, Lidocaine HCl displays an anti-convulsive effect.
Blood concentrations exceeding 5μg/ml may induce convulsions, underscoring the importance of careful dosage control.
){kind=link}